组织多肽抗原在卵巢癌诊断及监测中的应用

The Clinical Value of Tissue Polypeptide Antigen in Ovarian Carcinoma

目的评价组织多肽抗原（ＴＰＡ）在卵巢癌诊断和监测中的临床价值。方法应用放射免疫方法测定了２４例正常妇女、２７例妇科良性疾患及６０例卵巢癌患者的血清ＴＰＡ及ＣＡ１２５值并进行比较分析。结果ＴＰＡ在卵巢上皮性癌患者中的异常检出率为８２％，ＣＡ１２５为７０％，二者总的异常检出率为９２％。在绝大多数正常妇女和卵巢良性肿瘤患者中，ＣＡ１２５和ＴＰＡ在正常范围。作为卵巢癌相关标志物，ＴＰＡ与ＣＡ１２５具有相似敏感性。１９例动态观察结果显示，ＴＰＡ和ＣＡ１２５二者与病情转归是一致的。结论ＴＰＡ和ＣＡ１２５联合应用对卵巢癌的鉴别诊断及提高总的异常检出率具有价值。

Objective To evaluate the clinical usefulness of tissue polypeptide antigen (TPA) in diagnosis and monitoring the course of patients with ovarian carcinoma. Methods Serum levels of TPA and cancer antigen 125 (CA 125 )were measured by radioimmunoassay in 60 patients with advanced ovarian carcinoma (41 with active disease and 16 with nonactive, 3 with metastatic tumor from gastrointestinal carcinoma), 24 healthy women and 27 benign gynecologic tumors. Results The serum TPA and CA 125 levels were elevated in 82% and 70% of patients with ovarian carcinoma respectively, the total positive rate of the two markers was 92%. TPA and CA 125 levels were within normal range among most of healthy women and patients with benign tumors. TPA and CA 125 levels were also correlated with the regression or progression of the disease. Conclusion Combined measurement of TPA with CA 125 was useful for the differential diagnosis and achieving higher positivity in patients with epithelial ovarian carcinoma.